4.4 Article

Pulmonary alveolar proteinosis in pediatric leukemia

期刊

PEDIATRIC BLOOD & CANCER
卷 51, 期 1, 页码 66-70

出版社

WILEY-LISS
DOI: 10.1002/pbc.21442

关键词

alveolar macrophage; granulocyte-macrophage colony stimulating factor; leukemia; pediatric; pulmonary alveolar proteinosis

资金

  1. NCI NIH HHS [CA21765] Funding Source: Medline

向作者/读者索取更多资源

Background. Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by intra-alveolar accumulation of periodic acid-Schiff (PAS)-positive surfactant components. Leukemia is the cancer most often associated with PAP; prolonged neutropenia and reduction of alveolar macrophages by myeloablative chemotherapy or leukemic infiltration are implicated. Only isolated cases of PAP have been reported, and pediatric experience is limited. Procedure. We reviewed all pathology records (1962-2007) of St. Jude Children's Research Hospital to identify patients with PAP. Results. Five patients had PAP. As expected, all had leukemia and had profound neutropenia at onset of PAP. A diagnosis was made only after PAS staining of bronchoalveolar lavage (BAL), lung biopsy, or autopsy specimens. Two patients had Down syndrome, which is not known to be associated with PAP. The other three patients had undergone hematopoietic stem cell transplantation (HSCT). Two patients showed clinical improvement or histological disappearance of PAP after neutropenia resolved. Conclusions. PAP should be considered in the differential diagnosis of severe respiratory symptoms in neutropenic patients with hematologic malignancy, especially those with Down syndrome, a history of HSCT, or active disease. PAP should be confirmed by PAS staining of a BAL or lung biopsy specimen.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study

Andishe Attarbaschi, Anja Moericke, Christine J. Harrison, Georg Mann, Andre Baruchel, Barbara De Moerloose, Valentino Conter, Meenakshi Devidas, Sarah Elitzur, Gabriele Escherich, Stephen P. Hunger, Keizo Horibe, Atsushi Manabe, Mignon L. Loh, Rob Pieters, Kjeld Schmiegelow, Lewis B. Silverman, Jan Stary, Ajay Vora, Ching-Hon Pui, Martin Schrappe, Martin Zimmermann

Summary: This study aimed to investigate the prognostic factors and efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in the first remission of patients with noninfant childhood acute lymphoblastic leukemia (ALL) with 11q23/KMT2A rearrangements. The results showed that the prognosis of patients with noninfant 11q23/KMT2A-rearranged ALL has improved compared to historical data, but allo-HSCT did not improve outcomes. Targeted therapies are needed to reduce relapse and treatment-related mortality rates.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Letter Oncology

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki, Ellie R. Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K. Bergmann, Anja Moericke, Judith M. Boer, Helene Cave, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G. Mullighan, Mignon L. Loh, Ulrika Noren-Nystrom, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A. Haas, Christine J. Harrison, Anthony V. Moorman, Atsushi Manabe

LEUKEMIA (2023)

Article Oncology

Association between body mass index at diagnosis and outcomes in Chinese children with newly diagnosed acute lymphoblastic leukemia

Wenting Hu, Yin Ting Cheung, Yanjing Tang, Li Hong, Yuan Zhu, Jing Chen, Zhuo Wang, Min Zhou, Yijin Gao, Jing Chen, Benshang Li, Huiliang Xue, Longjun Gu, Shuhong Shen, Jingyan Tang, Ching-Hon Pui, Hiroto Inaba, Jiaoyang Cai

Summary: Studies on the association between BMI at diagnosis and treatment outcomes in Chinese children with ALL have shown inconsistent results. While weight status was not associated with event-free survival or overall survival, overweight patients were at a higher risk of treatment-related mortality.

CANCER MEDICINE (2023)

Article Hematology

Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis

David Spencer Mangum, Johnathon D. Bishop, Yinmei Zhou, Cheng Cheng, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Jun J. Yang, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Summary: Among children with acute lymphoblastic leukaemia, about 14.7% presented without peripheral blood blasts. While absence of blasts did not affect survival outcomes, these patients had distinct genetic and clinical characteristics, with a higher incidence of hyperdiploid B-ALL and lower rates of central nervous system involvement.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia

Chih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, Elane Coustan-Smith, Gang Wu, Chao-Neng Cheng, Meng-Yao Lu, Kai-Hsin Lin, Kang-Hsi Wu, Shu-Huey Chen, Fang-Liang Huang, Hsiu-Hao Chang, Jinn-Li Wang, Hsiu-Ju Yen, Meng-Ju Li, Shu-Wei Chou, Wan-Ling Ho, Yen-Lin Liu, Chia-Ching Chang, Ze-Shiang Lin, Chien-Yu Lin, Hsuan-Yu Chen, Yu-Ling Ni, Dong-Tsamn Lin, Shu-Wha Lin, Jun J. Yang, Yen-Hsuan Ni, Ching-Hon Pui, Sung-Liang Yu, Yung-Li Yang

Summary: This study analyzed data from two consecutive protocols to determine the clinical impact of minimal/measurable residual disease (MRD) and tumor genetic subtypes in newly diagnosed pediatric acute lymphoblastic leukemia (ALL) patients. The results showed that MRD-directed therapy improved outcomes for pediatric ALL, especially for standard-risk patients. This study provides important data to inform the design of future clinical trials in Taiwan.

CANCER (2023)

Article Biochemistry & Molecular Biology

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Shawn H. R. Lee, Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine R. R. Crews, Kathryn G. G. Roberts, Sima Jeha, Cheng Cheng, Seth E. E. Karol, Mary V. V. Relling, Gary L. L. Rosner, Hiroto Inaba, Charles G. G. Mullighan, Ching-Hon Pui, William E. E. Evans, Jun J. J. Yang

Summary: Contemporary chemotherapy for childhood acute lymphoblastic leukemia is personalized based on clinical features, leukemia genomics, and minimal residual disease. However, the pharmacological basis of these prognostic variables is unclear. A study analyzing samples from 805 children with newly diagnosed leukemia identified variations in drug response and determined that certain subtypes were more sensitive to specific agents. The findings suggest opportunities for individualizing therapy and exploring alternative strategies for childhood acute lymphoblastic leukemia.

NATURE MEDICINE (2023)

Article Oncology

Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods

Georgios E. Christakopoulos, Kendra N. Walker, Jesse Smith, Clifford M. Takemoto, Yan Zheng, Ching-Hon Pui, Raul C. Ribeiro, Lei Wang, Stanley B. Pounds, Jeffrey E. Rubnitz, Hiroto Inaba

Summary: This study investigated the clinical management strategies and effects of cytoreduction in pediatric patients with acute myeloid leukemia (AML) and hyperleukocytosis. The results showed that LD-cytarabine treatment was safe and effective in reducing leukocyte counts in children with AML and hyperleukocytosis.

CANCER (2023)

Article Oncology

Feasibility of indocyanine green-guided localization of pulmonary nodules in children with solid tumors

Abdelhafeez H. H. Abdelhafeez, Suraj Sarvode Mothi, Luca Pio, Motomi Mori, Teresa C. C. Santiago, M. Beth McCarville, Sue C. C. Kaste, Alberto S. S. Pappo, Lindsay J. J. Talbot, Andrew J. J. Murphy, Andrew M. M. Davidoff

Summary: ICG-guided identification of pulmonary nodules is not feasible for all pediatric solid tumors. However, it may be useful for localizing most metastatic hepatic tumors and high-grade sarcomas in children.

PEDIATRIC BLOOD & CANCER (2023)

Editorial Material Oncology

Introduction to the COG Diagnostic Imaging Committee/SPR Oncology Committee White Papers: Rationale and methods

E. R. Tang, A. L. Alazraki, P. G. Thacker, M. B. McCarville, A. J. Towbin

Summary: Pediatric cancer imaging requires experienced radiologists due to its rarity. The Children's Oncology Group Diagnostic Imaging Committee and the Society for Pediatric Radiology Oncology Committee, composed of experts in pediatric cancer imaging, have recently created a series of 23 White Papers as evidence-based imaging recommendations and protocols. This manuscript describes the methods employed in authoring the White Paper series.

PEDIATRIC BLOOD & CANCER (2023)

Correction Multidisciplinary Sciences

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia (vol 14, 809, 2023)

Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, William C. Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy, Tanja A. Gruber

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, William C. Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy, Tanja A. Gruber

Summary: Proteasome inhibition is found to be effective in KMT2Ar infant acute lymphoblastic leukemia, leading to the depletion of histone modifications and downregulation of KMT2A gene expression signature. A cohort of relapsed/refractory KMT2Ar patients treated with this approach showed a high overall response rate. This innovative treatment approach is now being evaluated in a multi-institutional upfront trial for infants with newly diagnosed ALL.

NATURE COMMUNICATIONS (2023)

Article Hematology

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia

Seth E. Karol, Elaine Coustan-Smith, Stanley Pounds, Lei Wang, Hiroto Inaba, Raul C. Ribeiro, Ching-Hon Pui, Jeffery M. Klco, Jeffrey E. Rubnitz

Summary: The prognostic significance of bone marrow minimal residual disease (MRD) in pediatric patients with acute myeloid leukemia (AML) is well characterized. However, the impact of blood MRD is not known. In this study, flow cytometric assessment of leukemia-specific immunophenotypes was used to measure levels of MRD in both the blood and bone marrow of patients treated in a clinical trial. Results showed that day-8 blood MRD was highly predictive of the outcome among patients who tested as having MRD-positive bone marrow on day 22, suggesting its potential as a tool for early identification and treatment of high-risk patients.

BLOOD ADVANCES (2023)

Meeting Abstract Oncology

COVID-19 IN ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA: ST JUDE CHILDREN'S RESEARCH HOSPITAL EXPERIENCE

Jessica Bodea, Saman Hashmi, Tushar Patni, Savannah Angel, Diego Hijano, Yimei Li, Hiroto Inaba

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

SIOP pediatric oncology services Global Mapping Program: Latin American data collection

Luisa Chantada, Maite Gorostegui, Jennifer Lowe, Neil Ranasinghe, Lucas Villegas, Jennifer Geel, Scott Howard, Eric Bouffet, Guillermo Chantada, Julia Challinor, Andrea Cappellano

Summary: The International Society of Paediatric Oncology (SIOP) and the Sociedad Latino Americana de Oncologia Pediatrica (SLAOP) collaborated to collect data on pediatric cancer facilities in Latin America. Data were collected through email, online meetings, or telephone calls, and stored in a secure platform.

PEDIATRIC BLOOD & CANCER (2023)

暂无数据